Andrei Gafita1,2, Hui Wang2, Andrew Robertson2, Wesley R Armstrong3, Raphael Zaum2, Manuel Weber4, Farid Yagubbayli2, Clemens Kratochwil5, Tristan R Grogan6, Kathleen Nguyen3, Fernando Navarro2,7, Rouzbeh Esfandiari8, Isabel Rauscher2, Bjoern Menze7,9, David Elashoff6, Ebrahim S Delpassand8, Ken Herrmann4, Johannes Czernin3, Michael S Hofman10, Jeremie Calais3, Wolfgang P Fendler4, Matthias Eiber2. 1. Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; agafita@mednet.ucla.edu. 2. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. 3. Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California. 4. Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany. 5. Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany. 6. Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California. 7. Department of Informatics, Technical University Munich, Munich, Germany. 8. Excel Diagnostics and Nuclear Oncology Center, Houston, Texas. 9. Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland; and. 10. Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Abstract
We aimed to systematically determine the impact of tumor burden on 68Ga-prostate-specific membrane antigen-11 (68Ga-PSMA) PET biodistribution by the use of quantitative measurements. Methods: This international multicenter, retrospective analysis included 406 men with prostate cancer who underwent 68Ga-PSMA PET/CT. Of these, 356 had positive findings and were stratified by quintiles into a very low (quintile 1, ≤25 cm3), low (quintile 2, 25-189 cm3), moderate (quintile 3, 189-532 cm3), high (quintile 4, 532-1,355 cm3), or very high (quintile 5, ≥1,355 cm3) total PSMA-positive tumor volume (PSMA-VOL). PSMA-VOL was obtained by semiautomatic segmentation of total tumor lesions using qPSMA software. Fifty prostate cancer patients with no PSMA-positive lesions (negative scan) served as a control group. Normal organs, which included salivary glands, liver, spleen, and kidneys, were semiautomatically segmented using 68Ga-PSMA PET images, and SUVmean was obtained. Correlations between the SUVmean of normal organs and PSMA-VOL as continuous and categoric variables by quintiles were evaluated. Results: The median PSMA-VOL was 302 cm3 (interquartile range [IQR], 47-1,076 cm3). The median SUVmean of salivary glands, kidneys, liver, and spleen was 10.0 (IQR, 7.7-11.8), 26.0 (IQR, 20.0-33.4), 3.7 (IQR, 3.0-4.7), and 5.3 (IQR, 4.0-7.2), respectively. PSMA-VOL showed a moderate negative correlation with the SUVmean of the salivary glands (r = -0.44, P < 0.001), kidneys (r = -0.34, P < 0.001), and liver (r = -0.30, P < 0.001) and a weak negative correlation with the spleen SUVmean (r = -0.16, P = 0.002). Patients with a very high PSMA-VOL (quintile 5, ≥1,355 cm3) had a significantly lower PSMA uptake in the salivary glands, kidneys, liver, and spleen than did the control group, with an average difference of -38.1%, -40.0%, -43.2%, and -34.9%, respectively (P < 0.001). Conclusion: Tumor sequestration affects 68Ga-PSMA biodistribution in normal organs. Patients with a very high tumor load showed a significantly lower uptake of 68Ga-PSMA in normal organs, confirming a tumor sink effect. As similar effects might occur with PSMA-targeted radioligand therapy, these patients might benefit from increased therapeutic activity without exceeding the radiation dose limit for organs at risk.
We aimed to systematically determine the impact of tumor burden on 68Ga-prostate-specific membrane antigen-11 (68Ga-PSMA) PET biodistribution by the use of quantitative measurements. Methods: This international multicenter, retrospective analysis included 406 men with prostate cancer who underwent 68Ga-PSMA PET/CT. Of these, 356 had positive findings and were stratified by quintiles into a very low (quintile 1, ≤25 cm3), low (quintile 2, 25-189 cm3), moderate (quintile 3, 189-532 cm3), high (quintile 4, 532-1,355 cm3), or very high (quintile 5, ≥1,355 cm3) total PSMA-positive tumor volume (PSMA-VOL). PSMA-VOL was obtained by semiautomatic segmentation of total tumor lesions using qPSMA software. Fifty prostate cancer patients with no PSMA-positive lesions (negative scan) served as a control group. Normal organs, which included salivary glands, liver, spleen, and kidneys, were semiautomatically segmented using 68Ga-PSMA PET images, and SUVmean was obtained. Correlations between the SUVmean of normal organs and PSMA-VOL as continuous and categoric variables by quintiles were evaluated. Results: The median PSMA-VOL was 302 cm3 (interquartile range [IQR], 47-1,076 cm3). The median SUVmean of salivary glands, kidneys, liver, and spleen was 10.0 (IQR, 7.7-11.8), 26.0 (IQR, 20.0-33.4), 3.7 (IQR, 3.0-4.7), and 5.3 (IQR, 4.0-7.2), respectively. PSMA-VOL showed a moderate negative correlation with the SUVmean of the salivary glands (r = -0.44, P < 0.001), kidneys (r = -0.34, P < 0.001), and liver (r = -0.30, P < 0.001) and a weak negative correlation with the spleen SUVmean (r = -0.16, P = 0.002). Patients with a very high PSMA-VOL (quintile 5, ≥1,355 cm3) had a significantly lower PSMA uptake in the salivary glands, kidneys, liver, and spleen than did the control group, with an average difference of -38.1%, -40.0%, -43.2%, and -34.9%, respectively (P < 0.001). Conclusion: Tumor sequestration affects 68Ga-PSMA biodistribution in normal organs. Patients with a very high tumor load showed a significantly lower uptake of 68Ga-PSMA in normal organs, confirming a tumor sink effect. As similar effects might occur with PSMA-targeted radioligand therapy, these patients might benefit from increased therapeutic activity without exceeding the radiation dose limit for organs at risk.
Authors: Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2017-06 Impact factor: 9.236
Authors: Janet H Pollard; Caleb Raman; Yousef Zakharia; Chad R Tracy; Kenneth G Nepple; Tim Ginader; Patrick Breheny; John J Sunderland Journal: J Nucl Med Date: 2019-12-05 Impact factor: 10.057
Authors: Andrei Gafita; Wolfgang P Fendler; Wang Hui; Shahneen Sandhu; Manuel Weber; Rouzbeh Esfandiari; Jeremie Calais; Isabel Rauscher; Hendrik Rathke; Robert Tauber; Ebrahim S Delpassand; Wolfgang A Weber; Ken Herrmann; Johannes Czernin; Matthias Eiber; Michael S Hofman Journal: Eur Urol Date: 2020-06-10 Impact factor: 20.096
Authors: Andrei Gafita; Jeremie Calais; Tristan R Grogan; Boris Hadaschik; Hui Wang; Manuel Weber; Shahneen Sandhu; Clemens Kratochwil; Rouzbeh Esfandiari; Robert Tauber; Anna Zeldin; Hendrik Rathke; Wesley R Armstrong; Andrew Robertson; Pan Thin; Calogero D'Alessandria; Matthew B Rettig; Ebrahim S Delpassand; Uwe Haberkorn; David Elashoff; Ken Herrmann; Johannes Czernin; Michael S Hofman; Wolfgang P Fendler; Matthias Eiber Journal: Lancet Oncol Date: 2021-07-08 Impact factor: 41.316
Authors: Benedikt Feuerecker; Robert Tauber; Karina Knorr; Matthias Heck; Ali Beheshti; Christof Seidl; Frank Bruchertseifer; Anja Pickhard; Andrei Gafita; Clemens Kratochwil; Margitta Retz; Jürgen E Gschwend; Wolfgang A Weber; Calogero D'Alessandria; Alfred Morgenstern; Matthias Eiber Journal: Eur Urol Date: 2020-12-05 Impact factor: 20.096
Authors: John Violet; Shahneen Sandhu; Amir Iravani; Justin Ferdinandus; Sue-Ping Thang; Grace Kong; Aravind Ravi Kumar; Tim Akhurst; David A Pattison; Alexis Beaulieu; Jennifer Mooi; Ben Tran; Christina Guo; Victor Kalff; Declan G Murphy; Price Jackson; Peter Eu; Mark Scalzo; Scott Williams; Rodney J Hicks; Michael S Hofman Journal: J Nucl Med Date: 2019-11-15 Impact factor: 11.082
Authors: Benjamin L Viglianti; Daniel J Wale; Ka Kit Wong; Timothy D Johnson; Christy Ky; Kirk A Frey; Milton D Gross Journal: Radiology Date: 2018-03-20 Impact factor: 11.105
Authors: Youssra Allach; Amina Banda; Willemijn van Gemert; Michel de Groot; Yvonne Derks; Melline Schilham; Alexander Hoepping; Lars Perk; Martin Gotthardt; Marcel Janssen; James Nagarajah; Bastiaan M Privé Journal: Cancers (Basel) Date: 2022-04-21 Impact factor: 6.639
Authors: Andreas K Buck; Rudolf A Werner; Sebastian E Serfling; Constantin Lapa; Niklas Dreher; Philipp E Hartrampf; Steven P Rowe; Takahiro Higuchi; Andreas Schirbel; Alexander Weich; Stefanie Hahner; Martin Fassnacht Journal: Mol Imaging Biol Date: 2022-03-21 Impact factor: 3.484
Authors: Song Xue; Andrei Gafita; Chao Dong; Yu Zhao; Giles Tetteh; Bjoern H Menze; Sibylle Ziegler; Wolfgang Weber; Ali Afshar-Oromieh; Axel Rominger; Matthias Eiber; Kuangyu Shi Journal: Eur J Nucl Med Mol Imaging Date: 2022-06-30 Impact factor: 10.057